After finishing at $2.88 in the prior trading day, Organogenesis Holdings Inc (NASDAQ: ORGO) closed at $2.76, down -4.17%. On the day, 722323 shares were traded.
Ratios:
Our goal is to gain a better understanding of ORGO by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.49 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 55.60. For the most recent quarter (mrq), Quick Ratio is recorded 2.44 and its Current Ratio is at 2.80. In the meantime, Its Debt-to-Equity ratio is 0.43 whereas as Long-Term Debt/Eq ratio is at 0.36.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on February 07, 2024, initiated with a Overweight rating and assigned the stock a target price of $5.
On June 15, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $5.
BTIG Research Upgraded its Neutral to Buy on May 24, 2023, while the target price for the stock was maintained at $10.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 10 ’24 when ERANI ALBERT sold 17,972 shares for $4.28 per share. The transaction valued at 76,875 led to the insider holds 59,007,134 shares of the business.
ERANI ALBERT sold 17,972 shares of ORGO for $76,875 on Jan 10 ’24. The 10% Owner now owns 59,007,134 shares after completing the transaction at $4.28 per share. On Jan 09 ’24, another insider, ERANI ALBERT, who serves as the 10% Owner of the company, sold 197,921 shares for $4.37 each. As a result, the insider received 863,985 and left with 59,025,106 shares of the company.
Valuation Measures:
As of this moment, Organogenesis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 75.20, and their Forward P/E ratio for the next fiscal year is 33.12. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 31.21. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.84 while its Price-to-Book (P/B) ratio in mrq is 1.30.
Stock Price History:
Over the past 52 weeks, ORGO has reached a high of $4.70, while it has fallen to a 52-week low of $1.79.
Shares Statistics:
A total of 131.32M shares are outstanding, with a floating share count of 77.29M. Insiders hold about 41.43% of the company’s shares, while institutions hold 44.54% stake in the company.
Earnings Estimates
Its stock is currently analyzed by Origin Materials, Inc. different market analysts. The consensus estimate for the next quarter is $30.13, with high estimates of $2.76 and low estimates of $2.35.
Analysts are recommending an EPS of between $Healthcare and $Industrials for the fiscal current year, implying an average EPS of $Healthcare.
